PMID- 35954442
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220815
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 15
DP  - 2022 Aug 3
TI  - Exosomes from EGFR-Mutated Adenocarcinoma Induce a Hybrid EMT and MMP9-Dependant 
      Tumor Invasion.
LID - 10.3390/cancers14153776 [doi]
LID - 3776
AB  - Exosomes, a class of extra cellular nano-sized vesicles (EVs), and their contents 
      have gained attention as potential sources of information on tumor detection and 
      regulatory drivers of tumor progression and metastasis. The effect of exosomes 
      isolated from patients with an Epidermal Growth Factor Receptor (EGFR)-mutated 
      adenocarcinoma on the promotion of epithelial-mesenchymal transition (EMT) and 
      invasion were examined. Exosomes derived from serum of patients with EGFR-mutated 
      non-small cell lung cancer (NSCLC) mediate the activation of the Phosphoinositide 
      3-kinase (PI3K)/AKT/ mammalian target of rapamycin (mTOR) pathway and induce an 
      invasion through the up-regulation of matrix metalloproteinase-9 (MMP-9) in A549 
      cells. We observed a significant increase in the expression of vimentin, a 
      mesenchymal marker, while retaining the epithelial characteristics, as evidenced 
      by the unaltered levels of E-cadherin and Epithelial cell adhesion molecule 
      (EPCAM). We also observed an increase of nuclear factor erythroid 2-related 
      factor 2 (NFR2) and P-cadherin expression, markers of hybrid EMT. Exosomes 
      derived from EGFR-mutated adenocarcinoma serum could be a potential mediator of 
      hybrid EMT and tumor invasion. Understanding how cancerous cells communicate and 
      interact with their environment via exosomes will improve our understanding of 
      lung cancer progression and metastasis formation.
FAU - Jouida, Amina
AU  - Jouida A
AUID- ORCID: 0000-0002-0042-5784
AD  - School of Medicine, University College Dublin, D14 E099 Dublin, Ireland.
FAU - O'Callaghan, Marissa
AU  - O'Callaghan M
AD  - School of Medicine, University College Dublin, D14 E099 Dublin, Ireland.
AD  - Department of Respiratory Medicine, St. Vincent's University Hospital, D04 T6F4 
      Dublin, Ireland.
FAU - Mc Carthy, Cormac
AU  - Mc Carthy C
AUID- ORCID: 0000-0003-2896-5210
AD  - School of Medicine, University College Dublin, D14 E099 Dublin, Ireland.
AD  - Department of Respiratory Medicine, St. Vincent's University Hospital, D04 T6F4 
      Dublin, Ireland.
FAU - Fabre, Aurelie
AU  - Fabre A
AD  - School of Medicine, University College Dublin, D14 E099 Dublin, Ireland.
AD  - Department of Respiratory Medicine, St. Vincent's University Hospital, D04 T6F4 
      Dublin, Ireland.
FAU - Nadarajan, Parthiban
AU  - Nadarajan P
AD  - School of Medicine, University College Dublin, D14 E099 Dublin, Ireland.
AD  - Department of Respiratory Medicine, St. Vincent's University Hospital, D04 T6F4 
      Dublin, Ireland.
FAU - Keane, Michael P
AU  - Keane MP
AUID- ORCID: 0000-0003-4507-0742
AD  - School of Medicine, University College Dublin, D14 E099 Dublin, Ireland.
AD  - Department of Respiratory Medicine, St. Vincent's University Hospital, D04 T6F4 
      Dublin, Ireland.
LA  - eng
PT  - Journal Article
DEP - 20220803
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9367273
OTO - NOTNLM
OT  - EGFR
OT  - exosome
OT  - lung cancer
OT  - partial EMT
COIS- The authors declare no conflict of interest.
EDAT- 2022/08/13 06:00
MHDA- 2022/08/13 06:01
PMCR- 2022/08/03
CRDT- 2022/08/12 01:05
PHST- 2022/06/28 00:00 [received]
PHST- 2022/07/23 00:00 [revised]
PHST- 2022/07/26 00:00 [accepted]
PHST- 2022/08/12 01:05 [entrez]
PHST- 2022/08/13 06:00 [pubmed]
PHST- 2022/08/13 06:01 [medline]
PHST- 2022/08/03 00:00 [pmc-release]
AID - cancers14153776 [pii]
AID - cancers-14-03776 [pii]
AID - 10.3390/cancers14153776 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Aug 3;14(15):3776. doi: 10.3390/cancers14153776.